NovoSeven RT- the new formulation of NovoSeven Coagulation Factor VIIa (Recombinant) – contains sucrose and L-Methionine, which allow for storage at room temperature. This is helpful for health-care facilities with limited refrigerated space. The original formula could be stored for three years at temperatures between 36 and 46 degrees Fahrenheit.
NovoSeven RT shares the same uses as the earlier NovoSeven product. These uses include the treatment of bleeding and the prevention of surgical bleeding in patients with hemophilia A or B, who have antibodies that neutralize the action of clotting Factors VIII or IX, the treatment of bleeding and the prevention of surgical bleeding in patients with congenital Factor VII deficiency and the prevention of surgical bleeding in patients with acquired hemophilia.
NovoSeven RT and NovoSeven Coagulation Factor VIIa (Recombinant) are manufactured by Novo Nordisk, located in Denmark.
Jesse Goodman, director of the FDA’s Center for Biologics Evaluation and Research, said: “Approval of this product for room temperature storage creates greater flexibility in disease management for both patients and physicians. As with all FDA-approved products, the agency will monitor NovoSeven RT throughout its life cycle.”